News

According to the World Health Organisation (WHO), death toll from the Ebola outbreak had rapidly increased to 2,296 out of 4,293 cases in five West African countries. So

The company would pursue approval via the 505(b)(2) regulatory pathway, based on discussions with the US Food and Drug Administration (FDA) and pending a successful development program. The

The newly issued patent claims cover compositions and methods for manufacturing vaccines utilizing ThermoVax, the Company’s proprietary vaccine thermostabilization technology. The new patent complements US patent 8,444,991, granted

Caduet Combination Tablets is an oral combination drug of hypertension treatment Norbasc Tablets sold by Pfizer, and Lipitor Tablets co-promoted by Pfizer and Astellas. As part of the

NuThrax is also known as AV7909, which is Emergent BioSolutions’ next generation anthrax vaccine candidate. The five-year, $29m contract provides funding for manufacturing and non-clinical activities through the

According to the company, treating rheumatoid arthritis at this critical early phase might prevent irreversible damage to joints and long-term disability. RoACTEMRA is the first interleukin-6 (IL-6) receptor

"COTI-2 is selectively active in in vivo and in vitro models with abnormal TP53. This is very exciting as TP53 is one of the "big three" of critically

Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg.

Under the Alliance Agreement, each company will contribute its specific expertise and resources with the objective of advancing biodefense products to be agreed to under individual product plans.